- Home
- KYMR
as 06-20-2025 4:00pm EST
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $59.38 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.45 - $53.27 | Next Earning Date: | 08-06-2025 |
| Revenue: | $58,885,000 | Revenue Growth: | -25.85% |
| Revenue Growth (this year): | 43.38% | Revenue Growth (next year): | 10.97% |
Stock Insider Trading Activity of Kymera Therapeutics Inc. (KYMR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ridloff Elena | KYMR | Director | Jun 11 '25 | Sell | $50.00 | 4,500 | $225,000.00 | 0 | |
| Albers Jeffrey W. | KYMR | Director | Jun 3 '25 | Sell | $49.00 | 6,349 | $311,101.00 | 0 | |
| Mainolfi Nello | KYMR | Chief Executive Officer | Jun 3 '25 | Sell | $49.00 | 30,000 | $1,470,000.00 | 660,482 | |
| Ridloff Elena | KYMR | Director | Jun 3 '25 | Sell | $46.25 | 12,000 | $553,200.00 | 0 | |
| Esposito Pamela | KYMR | Director | Jun 3 '25 | Sell | $49.04 | 5,000 | $245,185.50 | 0 | |
| Chadwick Jeremy G | KYMR | Chief Operating Officer | May 23 '25 | Sell | $29.30 | 2,575 | $75,435.66 | 66,420 |
Latest Kymera Therapeutics Inc. News
KYMR Breaking Stock News: Dive into KYMR Ticker-Specific Updates for Smart Investing
Investor's Business Daily
14 days ago
Kymera Therapeutics Stock Earns 92 RS Rating
Barrons.com
15 days ago
Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial
MT Newswires
17 days ago
Kymera Therapeutics Insider Sold Shares Worth $1,470,000, According to a Recent SEC Filing
Zacks
17 days ago
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
MT Newswires
17 days ago
Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says
MT Newswires
17 days ago
Stifel Adjusts Price Target on Kymera Therapeutics to $68 From $55, Maintains Buy Rating
MT Newswires
18 days ago
B. Riley Upgrades Kymera Therapeutics to Buy From Neutral, Adjusts Price Target to $60 From $38
MT Newswires
18 days ago
Morgan Stanley Upgrades Kymera Therapeutics to Overweight From Equalweight, Raises Price Target to $79 From $49
Compare KYMR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KYMR Kymera Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.